文献速递造血干细胞移植与细胞治疗

儿童异基因干细胞移植后计划性输注病毒特异性T细胞用于病毒预防

Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant.
PubMed 文献 · Blood Adv · 2022-01-01

该项临床试验(NCT03883906)评估了从干细胞供者快速制备四价病毒特异性T细胞(VST)并在异基因造血干细胞移植(HSCT)受者病毒血症极低或缺失时早期输注的可行性。23例患者接受计划性VST输注,20例输注时无病毒血症,3例有极低水平BK病毒血症。结论认为计划性VST看起来安全且可能有效限制病毒感染后的严重并发症,一项比较该计划性策略与用VST治疗活动性病毒血症的随机研究正在进行中。

要点

  • 23例患者接受计划性供者来源四价VST输注,最早可在干细胞输注后21天进行。
  • 20/23例输注时无病毒血症,3例有极低水平BK病毒血症;无输注反应发生。
  • 2例发生临床显著移植物抗宿主病(GVHD),经全身皮质类固醇治疗均成功。

核心结论

  • 计划性VST输注看起来安全且可能有效限制异基因移植后病毒感染的严重并发症。
  • 一项比较该计划性策略与用VST治疗活动性病毒血症的随机研究正在进行中。

研究设计与样本

  • 临床试验(NCT03883906),评估从干细胞供者快速制备四价VST并在异基因HSCT受者病毒血症极低或缺失时早期输注的可行性。
  • 患者最早可在干细胞输注后21天接受计划性VST输注。
  • 23例患者接受了计划性VST输注。

主要发现

  • 23例接受输注的患者中,20例输注时无病毒血症,3例有极低水平BK病毒血症。
  • 2例发生临床显著GVHD,该发生率未超出HSCT后早期预期范围,2例均经全身皮质类固醇治疗成功。
  • 5例被判定为治疗失败,其中3例随后发生显著病毒血症/病毒病。
  • 18例未治疗失败,其中7例未发生任何病毒血症,11例发生低水平自限性病毒血症且未经进一步干预自行消退。
  • 无输注反应发生。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infections with double-stranded DNA viruses are a significant cause of morbidity and mortality in pediatric patients following allogeneic hematopoietic stem cell transplantation (HSCT). Virus-specific T-cell therapies (VSTs) have been shown to be an effective treatment for infections with adenovirus, BK virus, cytomegalovirus (CMV), and Epstein-Barr virus (EBV). To date, prophylactic regimens to prevent or mitigate these infections using conventional antiviral medications provide suboptimal response rates. Here we report on a clinical trial (NCT03883906) performed to assess the feasibility of rapid manufacturing and early infusion of quadrivalent VSTs generated from stem cell donors ("donor-derived VSTs") into allogeneic HSCT recipients with minimal or absent viremia. Patients were eligible to receive scheduled VSTs as early as 21 days after stem cell infusion. Twenty-three patients received scheduled VSTs. Twenty of 23 patients had no viremia at the time of infusion, while 3 patients had very low-level BK viremia. Two developed clinically significant graft-versus-host disease (GVHD), although this incidence was not outside of expected incidence early after HSCT, and both were successfully treated with systemic corticosteroids (n = 2). Five patients were deemed treatment failures. Three developed subsequent significant viremia/viral disease (n = 3). Eighteen patients did not fail treatment, 7 of whom did not develop any viremia, while 11 developed low-level, self-limited viremia that resolved without further intervention. No infusion reactions occurred. In conclusion, scheduled VSTs appear to be safe and potentially effective at limiting serious complications from viral infections after allogeneic transplantation. A randomized study comparing this scheduled approach to the use of VSTs to treat active viremia is ongoing.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rubinstein JD, Lutzko C, Leemhuis T, et al. Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant. Blood Adv. 2022. PMID: 35108727. doi:10.1182/bloodadvances.2021006309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。